A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Status:
Active, not recruiting
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Open-label, multicentre phase Ib/IIa study of AZD2014 administered with selumetinib. There
are two parts to this study: a dose-escalation part in treatment-refractory advanced solid
tumours and a subsequent separate expansion cohort part for TNBC, squamous cell lung cancers,
non-squamous cell lung cancers with KRAS mutations and non-squamous cell lung cancers with
wild-type KRAS